| 查看: 732 | 回复: 1 | |||
[交流]
怎么翻译啊求助，JBT-101是什么求告知
|
|
abstract Ajulemic acid, a side-chain analog of D8 -THC-11-oic acid, was designed as a potent therapeutic agent free of the psychotropic adverse effects typical of most cannabinoids. Subsequent studies of ajulemic acid have yielded widely divergent findings on the occurrence of these adverse effects. To help resolve these discrepancies, we have prepared highly purified ajulemic acid using a different synthetic method than previously reported in the literature and compared its cannabinoid receptor binding constants with those obtained using several other preparations from different sources. Whereas CB2 binding did not vary greatly among all of the samples, the CB1 binding showed a wide range of affinities. The highly purified product (JBT-101) reported here had the weakest affinity for CB1 while the original preparation (HU-239) showed the strongest affinity for CB1. The CB1/CB2 ratio of affinities was 12.3 for JBT-101 whereas that for HU-239 was 0.19, a 65-fold difference. Functional responses such as catalepsy and hypothermia using JBT-101 versus HU-239 displayed reduced CB1 activity in keeping with the receptor binding data. Thus, earlier conclusions on the limited therapeutic index for ajulemic acid need to be reconsidered in the light of the data now obtained using JBT-101. 发自小木虫Android客户端 |
回复此楼» 猜你喜欢
国自然评审意见
已经有8人回复
-
国自然面上复盘~欢迎讨论
已经有14人回复
-
系统查不到
已经有11人回复
-
有多少人是今天查系统知道结果的？
已经有18人回复
-
为什么资助数各大高校都创新高，自己申请怎么就这么难
已经有12人回复
-
有没有仍没收到信息的
已经有3人回复
-
导师吐槽：我怎么摊上了这么个极品研究生！
已经有8人回复
-
基金不中，共勉
已经有11人回复
-
麻烦专家们看看评委们的意见（F口面上）
已经有9人回复
-
2026年叶企孙基金
已经有6人回复
|
abstract Ajulemic acid, a side-chain analog of D8 -THC-11-oic acid, was designed as a potent therapeutic agent free of the psychotropic adverse effects typical of most cannabinoids. Subsequent studies of ajulemic acid have yielded widely divergent findings on the occurrence of these adverse effects. To help resolve these discrepancies, we have prepared highly purified ajulemic acid using a different synthetic method than previously reported in the literature and compared its cannabinoid receptor binding constants with those obtained using several other preparations from different sources. Whereas CB2 binding did not vary greatly among all of the samples, the CB1 binding showed a wide range of affinities. The highly purified product (JBT-101) reported here had the weakest affinity for CB1 while the original preparation (HU-239) showed the strongest affinity for CB1. The CB1/CB2 ratio of affinities was 12.3 for JBT-101 whereas that for HU-239 was 0.19, a 65-fold difference. Functional responses such as catalepsy and hypothermia using JBT-101 versus HU-239 displayed reduced CB1 activity in keeping with the receptor binding data. Thus, earlier conclusions on the limited therapeutic index for ajulemic acid need to be reconsidered in the light of the data now obtained using JBT-101. 发自小木虫Android客户端 |
2楼2017-02-07 10:27:37
